Dry Macular Degeneration Clinical Trials
However, dry AMD clinical trials are not as prevalent as they are for wet age related macular degeneration.
Dry Macular Degeneration StudiesAs of April 2010, there are 22 trials listed on the U.S. National Institutes of Health website that are currently recruiting new participants.There are several things you want to consider when you consider a clinical trial.
Where is the Study Being ConductedThe clinical trials that are listed at www.clinicaltrials.gov are not just in the United States, but rather it is an international database. So it is important to look at the location of the study. Right now out of the 8 studies available, most of them are outside the United States. They are in in Israel, Canada, Switzerland, Austria, Sweden and Germany.
What Treatment is Being Investigated
Of the studies that are in the United States, one of them is testing the safety of transplanting human fetal neural retinal tissue and retinal pigment epithelium into the eyes of human patients with age-related macular degeneration.
The second study listed is "Weekly Vaccination With Copaxone as a Potential Therapy for Dry Age-Related Macular Degeneration." Copaxone is an immunomodulatory substance which has shown to be an effective drug in arresting the progression as well as the conversion of dry AMD to wet AMD.
What Phase is the Study InThere are four stages. Stage I being the first stage that tests for safety. The last is Stage IV. Click her for more detailed information: Clinical Trial PhasesTo perform a search of current clinical trials click on the link below and in the search field type in, "dry macular degeneration" without the quotes. www.ClinicalTrials.gov Here are some current macular degeneration studies for dry macular degeneration treatment: 1. Early Dry AMD Clinical Trial
Effect of Lutein-Enriched-Egg Beverage on Early AMDMaastricht University Medical Center did a pilot study in 2007 that showed a substantial increase in plasma lutein levels and a increase in macular pigment optical density after only 3 months of daily consumption of a lutein-enriched egg-beverage. They now want to study the effect these changes have on subjects with early (undiagnosed) stages of macular degeneration. With this trial they hope to show that with daily consumption of this enriched beverage, they can slow the progression of AMD. To learn more about the criteria and purpose of this study click here:
Lutein Enriched Egg Beverage Study for Early AMD
2. ACU-4429 in Subjects With Geographic AtrophyA Phase II clinical trial will be looking at the effectiveness of ACU-4429. This drug is meant to block the enzyme isomerase to help slow down the progression of dry AMD.This clinical trial is taking place in Austin and Dallas, Texas. Click here to find out more about this study and to get contact information:
3. Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy
This is a Phase I clinical trial which means it is primarily look at the safety and tolerability of the study drug which is an
intravitreal injection of FCFD4514S - which means it is injected into the eye.
You must be between the ages of 50 - to 85 years old and be diagnosed with geographic atrophy. There are 5 study locations - all in the United States. Click here to get the list of locations and contact information.
Intravitreal Injections of FCFD4514S in Patients With Geographic Atrophy 4. Weekly Vaccination With Copaxone as a Potential Therapy for Dry AMDThe stated purpose of this macular degeneration research is:"The purpose of the project is to investigate in eyes with dry AMD, the efficacy and safety as preventive therapy of the immunomodulatory substance named copaxone which had been proven as safe and effective agent for a neurodegenerative disease, in arresting the progression as well as the conversion of dry AMD to wet AMD. The hypothesis that the immunomodulatory agent copaxone proven for a neurodegenerative disease may work in the eye is revolutionary and may open a new avenue of preventive treatment for the disease which is the major cause of legal blindness in the industrial world." To be eligible for this study you must have Dry AMD in one or both eyes and age 50 or above. This study is at the New York Eye and Ear Infirmary Recruiting in New York, New York. The contact is Katy Tai, CCRC at ktai@nyee.edu
Go from Dry Macular Degeneration Clinical Trials to Macular Degeneration Clinical Trials
Would you like to be updated on the latest: 
√ Clinical Trials?
√ Prevention of Macular Degeneration? √ Tips for Daily Living? √ Food Suggestions for a Macular Degeneration Diet? √ Ideas on Visual Aids to Maximize your Sight? If you said "yes" to any of the above, sign up for my monthly Macular Degeneration News.
|
